| Autor: |
Beverly E, Sha, Hernan, Valdez, Rebecca S, Gelman, Alan L, Landay, Jan, Agosti, Ronald, Mitsuyasu, Richard B, Pollard, Donna, Mildvan, Ann, Namkung, Debra M, Ogata-Arakaki, Lawrence, Fox, Scharla, Estep, Alejo, Erice, Patrick, Kilgo, Robert E, Walker, Lynne, Bancroft, Michael M, Lederman |
| Rok vydání: |
2002 |
| Předmět: |
|
| Zdroj: |
AIDS research and human retroviruses. 18(9) |
| ISSN: |
0889-2229 |
| Popis: |
The effect of etanercept, a soluble p75 tumor necrosis factor (TNF) receptor:Fc fusion protein (Enbrel; Immunex, Seattle, WA) on plasma cytokines was evaluated in 11 HIV-infected subjects receiving highly active antiretroviral therapy (HAART) for 28 weeks with or without subcutaneous or intravenous recombinant human interleukin 2 (rhIL-2). Plasma IL-6 and C-reactive protein (CRP) levels increased after rhIL-2 treatment. Etanercept pretreatment attenuated these increases. Median plasma IL-6 levels were 20.29 pg/ml 4 days after rhIL-2 and 7.87 pg/ml 4 days after etanercept and rhIL-2 (p = 0.22); median CRP levels were 78.73 and 46.16 microg/ml, respectively (p = 0.03). An effect on TNF bioactivity could not be assessed as all measurements were below limits of detection. No significant changes were seen in temperature or plasma levels of IL-4, IL-10, IL-12, interferon gamma, or HIV-1 RNA levels. All subjects had undetectable or low-level HIV-1 RNA levels before etanercept dosing. One subject died; however, her death was thought to be unrelated to etanercept. Pretreatment with etanercept may blunt activation of IL-6 and CRP expression induced by rhIL-2. The safety and utility of etanercept in HIV-infected persons should be explored further. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
